QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, March 14, 2007, 27(11):2979-2986; doi:10.1523/JNEUROSCI.5416-06.2007

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Samaha, A.-N. Articles by Kapur, S. Search for Related Content PubMed PubMed Citation Articles by Samaha, A.-N. Articles by Kapur, S.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
"Breakthrough" Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time

Anne-Noël Samaha,¹ Philip Seeman,^2,3 Jane Stewart,⁴ Heshmat Rajabi,⁴ and Shitij Kapur^1,2

¹Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada M5T 1R8, ²Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5T 1R8, ³Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8, and ⁴Centre for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montréal, Quebec, Canada H4B 1R6

Correspondence should be addressed to Shitij Kapur, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario, Canada M5S 2S1. Email: Shitij_Kapur{at}camh.net

Antipsychotics often lose efficacy in patients despite chronic continuous treatment. Why this occurs is not known. It is known, however, that withdrawal from chronic antipsychotic treatment induces behavioral dopaminergic supersensitivity in animals. How this emerging supersensitivity might interact with ongoing treatment has never been assessed. Therefore, we asked whether dopamine supersensitivity could overcome the behavioral and neurochemical effects of antipsychotics while they are still in use. Using two models of antipsychotic-like effects in rats, we show that during ongoing treatment with clinically relevant doses, haloperidol and olanzapine progressively lose their efficacy in suppressing amphetamine-induced locomotion and conditioned avoidance responding. Treatment failure occurred despite high levels of dopamine D₂ receptor occupancy by the antipsychotic and was at least temporarily reversible by an additional increase in antipsychotic dose. To explore potential mechanisms, we studied presynaptic and postsynaptic elements of the dopamine system and observed that antipsychotic failure was accompanied by opposing changes across the synapse: tolerance to the ability of haloperidol to increase basal dopamine and dopamine turnover on one side, and 20–40% increases in D₂ receptor number and 100–160% increases in the proportion of D₂ receptors in the high-affinity state for dopamine (D₂^High) on the other. Thus, the loss of antipsychotic efficacy is linked to an increase in D₂ receptor number and sensitivity. These results are the first to demonstrate that "breakthrough" supersensitivity during ongoing antipsychotic treatment undermines treatment efficacy. These findings provide a model and a mechanism for antipsychotic treatment failure and suggest new directions for the development of more effective antipsychotics.

Key words: antipsychotics; dopamine; supersensitivity; dopamine D₂ receptors; high-affinity receptors; striatum

---

Received Dec. 14, 2006; revised Jan. 17, 2007; accepted Feb. 13, 2007.

Correspondence should be addressed to Shitij Kapur, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario, Canada M5S 2S1. Email: Shitij_Kapur{at}camh.net

This article has been cited by other articles:

				A. Goudie and J. Cole Switching antipsychotics. Antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications J Psychopharmacol, September 1, 2008; 22(7): 815 - 817. [PDF]

				J. de Leon, N. B. Sandson, and K. L. Cozza A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II Psychosomatics, July 1, 2008; 49(4): 347 - 361. [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help